In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Apellis Pharmaceuticals Inc (NASDAQ: APLS) closed the day trading at $21.47 up 3.57% from the previous closing price of $20.73. In other words, the price has increased by $3.57 from its previous closing price. On the day, 6.49 million shares were traded. APLS stock price reached its highest trading level at $21.7999 during the session, while it also had its lowest trading level at $19.26.
Ratios:
For a better understanding of APLS, let’s look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 5.65 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 34.54. For the most recent quarter (mrq), Quick Ratio is recorded 3.10 and its Current Ratio is at 3.54. In the meantime, Its Debt-to-Equity ratio is 1.18 whereas as Long-Term Debt/Eq ratio is at 0.93.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Wells Fargo on October 15, 2025, initiated with a Overweight rating and assigned the stock a target price of $32.
On September 26, 2025, Goldman Downgraded its rating to Sell which previously was Neutral but kept the price unchanged to $18.
Raymond James Downgraded its Strong Buy to Outperform on May 09, 2025, while the target price for the stock was maintained at $52.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 21 ’25 when Sullivan Timothy Eugene sold 10,000 shares for $28.03 per share. The transaction valued at 280,300 led to the insider holds 110,936 shares of the business.
Sullivan Timothy Eugene bought 10,000 shares of APLS for $280,300 on Oct 21 ’25. On Oct 16 ’25, another insider, Watson David O., who serves as the General Counsel of the company, sold 5,000 shares for $25.22 each. As a result, the insider received 126,100 and left with 113,730 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, APLS now has a Market Capitalization of 2716496384 and an Enterprise Value of 2711638528. As of this moment, Apellis’s Price-to-Earnings (P/E) ratio for their current fiscal year is 72.31. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.80. For the stock, the TTM Price-to-Sale (P/S) ratio is 2.67 while its Price-to-Book (P/B) ratio in mrq is 6.77. Its current Enterprise Value per Revenue stands at 2.668 whereas that against EBITDA is 33.035.
Stock Price History:
The Beta on a monthly basis for APLS is 0.69, which has changed by -0.24824929 over the last 52 weeks, in comparison to a change of 0.19736934 over the same period for the S&P500. Over the past 52 weeks, APLS has reached a high of $35.72, while it has fallen to a 52-week low of $16.10. The 50-Day Moving Average of the stock is -15.87%, while the 200-Day Moving Average is calculated to be -6.76%.
Shares Statistics:
Over the past 3-months, APLS traded about 2.54M shares per day on average, while over the past 10 days, APLS traded about 3850110 shares per day. A total of 126.50M shares are outstanding, with a floating share count of 104.60M. Insiders hold about 17.33% of the company’s shares, while institutions hold 103.44% stake in the company. Shares short for APLS as of 1760486400 were 18061349 with a Short Ratio of 7.11, compared to 1757894400 on 21758081. Therefore, it implies a Short% of Shares Outstanding of 18061349 and a Short% of Float of 18.84.
Earnings Estimates
The stock of Apellis Pharmaceuticals Inc (APLS) is currently being evaluated by 10.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.52, with high estimates of -$0.34 and low estimates of -$0.69.
Analysts are recommending an EPS of between $0.65 and -$2.21 for the fiscal current year, implying an average EPS of -$0.17. EPS for the following year is -$1.02, with 10.0 analysts recommending between $0.45 and -$1.87.
Revenue Estimates
17 analysts predict $203.65M in revenue for . The current quarter. It ranges from a high estimate of $232M to a low estimate of $184.6M. As of . The current estimate, Apellis Pharmaceuticals Inc’s year-ago sales were $212.53MFor the next quarter, 17 analysts are estimating revenue of $192.94M. There is a high estimate of $208.5M for the next quarter, whereas the lowest estimate is $169.15M.
A total of 19 analysts have provided revenue estimates for APLS’s current fiscal year. The highest revenue estimate was $1.05B, while the lowest revenue estimate was $698.26M, resulting in an average revenue estimate of $978.58M. In the same quarter a year ago, actual revenue was $781.37MBased on 18 analysts’ estimates, the company’s revenue will be $882.15M in the next fiscal year. The high estimate is $1.02B and the low estimate is $770.32M.
